Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 6:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 234 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Metabolism and Elimination Clear all
Completed Phase 1 Interventional

Study to Assess the Absorption, Distribution, Metabolism and Excretion of AZD1656 in Type 2 Diabetes Mellitus (T2DM)

NCT00960791
View directory record Official record
Conditions
Type II Diabetes Mellitus
Interventions
AZD1656
Device
Lead sponsor
AstraZeneca
Industry
Eligibility
35 Years to 65 Years · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
San Diego, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2009 · Synced Sep 25, 2026, 6:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Drug Levels of [14C]CC-99677 in Healthy Male Participants

NCT05284890
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CC-99677
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Sep 25, 2026, 6:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Assess Absolute Bioavailability of TAK-935 (OV935) and to Characterize Mass Balance, Pharmacokinetics, Metabolism, and Excretion of [14C]TAK-935 (OV935) in Healthy Male Participants

NCT04992442
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-935 Oral Tablet, [14C]TAK-935 IV Infusion, [14C]TAK-935 Oral Solution
Drug
Lead sponsor
Takeda
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 25, 2026, 6:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Radiolabeled Mass Balance Study Of [14C]PF-00299804 In Healthy Male Volunteers

NCT01034748
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
[14C]PF00299804
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Mar 11, 2010 · Synced Sep 25, 2026, 6:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Absorption, Metabolism, and Excretion and Estimation of the Absolute Bioavailability of K-312

NCT02676830
View directory record Official record
Conditions
Dyslipidemia
Interventions
K-312 100 mg, K-312 100 ug C14 IV
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
25 Years to 45 Years · Male only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Sep 25, 2026, 6:35 AM EDT
Terminated Phase 3 Interventional

ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial

NCT06828861
View directory record Official record
Conditions
Hyperphagia, Prader-Willi Syndrome
Interventions
Placebo, ARD-101
Drug
Lead sponsor
Aardvark Therapeutics, Inc.
Industry
Eligibility
7 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
17
States / cities
Birmingham, Alabama • Encinitas, California • Orange, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 25, 2026, 6:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Absorption, Metabolism, Excretion, and Mass Balance Study of [14C]-VVZ-149 in Healthy Adult Male Subjects

NCT04415645
View directory record Official record
Conditions
Healthy Adult Male
Interventions
[14C]-VVZ-149
Drug
Lead sponsor
Vivozon, Inc.
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 3, 2020 · Synced Sep 25, 2026, 6:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

AME Study of [14C]-YH4808 in Healthy Male Subjects

NCT01825707
View directory record Official record
Conditions
Healthy
Interventions
[14C]-YH4808 200 mg
Drug
Lead sponsor
Yuhan Corporation
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 13, 2014 · Synced Sep 25, 2026, 6:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Absorption, Metabolism, and Excretion of GBT440 in Healthy Male Subjects

NCT02497924
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
GBT440
Drug
Lead sponsor
Global Blood Therapeutics
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Sep 25, 2026, 6:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Radiolabeled [14C]PF-02341066 Study To Investigate The Absorption, Metabolism And Excretion In Healthy Male Volunteers

NCT01082380
View directory record Official record
Conditions
Healthy Volunteer
Interventions
PF-02341066
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Sep 25, 2026, 6:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Single Dose Study of [14C]-IDV184001AN ([14C]-IDV184001) in Healthy Adult Male Participants

NCT05974046
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
[14C]IDV184001AN
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Sep 25, 2026, 6:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Absorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled Prucalopride Succinate in Volunteers

NCT01807000
View directory record Official record
Conditions
Healthy
Interventions
Radiolabeled Prucalopride Succinate
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Sep 25, 2026, 6:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male Subjects

NCT05225389
View directory record Official record
Conditions
Alzheimer Disease
Interventions
300 mg [C14] CT1812
Drug
Lead sponsor
Cognition Therapeutics
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Sep 25, 2026, 6:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Understand How the Study Medicine Called ARV-471 is Processed in Healthy Adults

NCT05930925
View directory record Official record
Conditions
Healthy
Interventions
[phenyl-14C]ARV-471, [oxoisoindolin-14C]ARV-471
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 25, 2026, 6:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Understand How Radiolabelled PF-04449913 Is Taken Up By The Body, Broken Down And Then Removed From The Body

NCT02110342
View directory record Official record
Conditions
Healthy
Interventions
[14C] PF-04449913
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Sep 25, 2026, 6:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

AME (Absorption, Metabolism, and Excretion) of Radiolabeled SSP-004184

NCT01824446
View directory record Official record
Conditions
Healthy
Interventions
Radiolabeled SPD602 (FBS0701, SSP-004184)
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Sep 25, 2026, 6:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Flavanol Absorption, Metabolism and Excretion From Fruit-based Drinks and Other Food Matrixes

NCT03526094
View directory record Official record
Conditions
Healthy
Interventions
Flavanols-capsules, Flavanol-banana blend, Flavanol-high protein drink, Flavanol-berry blend, Flavanol-sports drink, Flavanol-peanut butter toast, Flavanol-oats, Flavanol-yogurt, II- Flavanol drink, II- Flavanol drink + banana blend
Other
Lead sponsor
University of California, Davis
Other
Eligibility
25 Years to 60 Years · Male only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2022 · Synced Sep 25, 2026, 6:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-DNL343 Following a Single Oral Dose in Healthy Male Participants

NCT06281158
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[14C]-DNL343
Drug
Lead sponsor
Denali Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 19, 2024 · Synced Sep 25, 2026, 6:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of [4-14C] AEF0117 Following a Single Oral Dose in Healthy Male Subjects

NCT05554926
View directory record Official record
Conditions
Marijuana Abuse
Interventions
AEF0117
Drug
Lead sponsor
Aelis Farma
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Sep 25, 2026, 6:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of [3H] BMS747158 in Healthy Male Subjects

NCT00930631
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
[3H] BMS747158
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Sep 25, 2026, 6:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Radiolabel ADME (Absorption, Distribution, Metabolism, and Excretion) Study Of [14C] PF-00868554 In Healthy Adult Male Subjects

NCT00823745
View directory record Official record
Conditions
HCV
Interventions
[14C]-PF-00868554
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Mar 8, 2009 · Synced Sep 25, 2026, 6:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-0980 Following Single Oral Dose Administration in Healthy Postmenopausal Female Subjects

NCT01487239
View directory record Official record
Conditions
Healthy Volunteer
Interventions
[14C]-GDC-0980
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 25, 2026, 6:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Adult Female Subjects

NCT05339633
View directory record Official record
Conditions
Mass Balance Recovery
Interventions
[14C]-D-0502
Drug
Lead sponsor
InventisBio Co., Ltd
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Sep 25, 2026, 6:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

RE104 Radiolabeled Mass Balance (hAME) Study

NCT07146191
View directory record Official record
Conditions
Healthy Participant Study
Interventions
2-[14C]-RE104 for Injection
Drug
Lead sponsor
Reunion Neuroscience Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Sep 25, 2026, 6:35 AM EDT